rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A missense mutation was found at T1796A (V599E) in exon 15 in four of the six cell lines and 51 of 207 thyroid tumors (24.6%; 0 of 20 follicular adenoma, 0 of 11 follicular carcinoma, 49 of 170 papillary carcinomas, and 2 of 6 undifferentiated carcinomas).
|
12970315 |
2003 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A missense mutation was found at T1796A (V599E) in exon 15 in four of the six cell lines and 51 of 207 thyroid tumors (24.6%; 0 of 20 follicular adenoma, 0 of 11 follicular carcinoma, 49 of 170 papillary carcinomas, and 2 of 6 undifferentiated carcinomas).
|
12970315 |
2003 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These data clearly confirm that BRAF(V599E) is the more common genetic alteration found to date in adult sporadic PTCs, that it is unique for this thyroid cancer histotype, and that it might drive the development of PTCs of the classic papillary subtype.
|
15126572 |
2004 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These data clearly confirm that BRAF(V599E) is the more common genetic alteration found to date in adult sporadic PTCs, that it is unique for this thyroid cancer histotype, and that it might drive the development of PTCs of the classic papillary subtype.
|
15126572 |
2004 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We isolated genomic DNA from primary thyroid tumors and paired lymph node metastases and performed direct sequencing of exon 15 of the BRAF gene mutation that carries the T1799A mutation.
|
15998781 |
2005 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The BRAF(V600E) mutation was detected in tumour samples from 31 of 60 conventional micro-PTC patients (52%), but was not detected in patients with other types of thyroid tumours.
|
16268813 |
2005 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The BRAF(V600E) mutation was detected in tumour samples from 31 of 60 conventional micro-PTC patients (52%), but was not detected in patients with other types of thyroid tumours.
|
16268813 |
2005 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF provides signals crucial for proliferation of thyroid carcinoma cells spontaneously harboring the (V600E)BRAF mutation and, therefore, BRAF suppression might have therapeutic potential in (V600E)BRAF-positive thyroid cancer.
|
16533790 |
2006 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In Korea, most thyroid cancer is the classic papillary type and the BRAF(V600E) mutation is highly prevalent.
|
17054470 |
2006 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
They also potently blocked MEK phosphorylation in human thyroid cancer cell lines with either RET/PTC1 (TPC1) or BRAF(V600E) (NPA, ARO, and FRO) mutations.
|
16551863 |
2006 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In Korea, most thyroid cancer is the classic papillary type and the BRAF(V600E) mutation is highly prevalent.
|
17054470 |
2006 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF provides signals crucial for proliferation of thyroid carcinoma cells spontaneously harboring the (V600E)BRAF mutation and, therefore, BRAF suppression might have therapeutic potential in (V600E)BRAF-positive thyroid cancer.
|
16533790 |
2006 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
They also potently blocked MEK phosphorylation in human thyroid cancer cell lines with either RET/PTC1 (TPC1) or BRAF(V600E) (NPA, ARO, and FRO) mutations.
|
16551863 |
2006 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
After treatment with the potent MEK 1/2 inhibitor AZD6244, MEK inhibition and cell growth were examined in four BRAF mutant (V600E) and two BRAF wild-type thyroid cancer cell lines and in xenografts from a BRAF mutant cell line.
|
17878251 |
2007 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutation status was determined in 347 tumor samples from 314 patients with thyroid cancer (245 with conventional papillary thyroid cancer, 73 with follicular thyroid cancer, and 29 with the follicular variant of papillary thyroid cancer).
|
17717450 |
2007 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Small molecule inhibitors that selectively target B-Raf(V600E) may provide clinical benefit for patients with thyroid cancer.
|
17363500 |
2007 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
After treatment with the potent MEK 1/2 inhibitor AZD6244, MEK inhibition and cell growth were examined in four BRAF mutant (V600E) and two BRAF wild-type thyroid cancer cell lines and in xenografts from a BRAF mutant cell line.
|
17878251 |
2007 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutation status was determined in 347 tumor samples from 314 patients with thyroid cancer (245 with conventional papillary thyroid cancer, 73 with follicular thyroid cancer, and 29 with the follicular variant of papillary thyroid cancer).
|
17717450 |
2007 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Small molecule inhibitors that selectively target B-Raf(V600E) may provide clinical benefit for patients with thyroid cancer.
|
17363500 |
2007 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Dideoxy sequencing is the most commonly used method for detecting the BRAF(V600E) mutation in thyroid cancer and melanoma.
|
18462259 |
2009 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In many cancers, including thyroid cancer, B-Raf(V600E) appears to play a crucial role in cell proliferation, survival and de-differentiation.
|
19356676 |
2009 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our results in thyroid cancer cells, namely those harbouring BRAF(V600E) mutation showed that BRAF signalling pathway provides important proliferation signals.
|
19878585 |
2009 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We developed an allele-specific real-time PCR method for the detection of BRAF(T1799A) in blood samples and studied prospectively blood samples from 193 patients with thyroid cancer (173 PTC, 20 non-PTC) attending for routine follow-up.
|
19850689 |
2009 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In many cancers, including thyroid cancer, B-Raf(V600E) appears to play a crucial role in cell proliferation, survival and de-differentiation.
|
19356676 |
2009 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our results in thyroid cancer cells, namely those harbouring BRAF(V600E) mutation showed that BRAF signalling pathway provides important proliferation signals.
|
19878585 |
2009 |